Escalon Medical Corp. (ESMC) Stock Price & Analysis
Escalon Medical Corp. (ESMC) closed at USD 0.17 on Friday, October 23, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.17; the Oct 23, 2026 session ranged USD 0.18–0.18 on volume of 5,300 shares. Market capitalization is $1.26M, with a 52-week range of USD 0.14–0.29 (OQB). Source: Nexqual, retrieved October 24, 2026 at 21:02 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ESMC.md
Key facts (ESMC)
- Last four reported quarters (through Jun 30, 2026): revenue $12.7M, net income $4.0M (31.5% margin), free cash flow -$407K (SEC filings).
- Valuation: P/E 0.3x (avg 22.0x at the last 2 fiscal year-ends).
- Analysts: None.
- Total return with dividends: 1Y +6.3% vs S&P 500 +13.4%; 5Y -15.0% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ESMC)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $10.7M | $12.2M | $12.0M | $12.0M | $12.7M | $12.7M |
| Gross profit | $4.6M | $5.5M | $5.1M | $5.5M | $5.6M | — |
| Operating income | -$470K | $479K | -$104K | $133K | $45K | $45K |
| Net income | $18K | $457K | -$125K | $106K | $4.0M | $4.0M |
| EPS (diluted) | $0.00 | $0.03 | -$0.02 | $0.00 | $0.27 | — |
| Free cash flow | -$1.0M | $318K | -$643K | $377K | -$407K | -$407K |
| Gross margin | 43.0% | 45.0% | 43.0% | 45.7% | 43.7% | — |
| Operating margin | -4.4% | 3.9% | -0.9% | 1.1% | 0.4% | 0.4% |
| Net margin | 0.2% | 3.8% | -1.0% | 0.9% | 31.5% | 31.5% |
| Revenue growth | +2.2% | +13.8% | -1.6% | +0.5% | +5.7% | — |
| Cash + short-term investments | $594K | $890K | $209K | $546K | $3.1M | — |
Fiscal years end Jun. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ESMC)
P/E 0.3x · P/S 0.1x · P/B 0.2x · FCF yield -32.29% · Earnings yield 318.31%
P/E at fiscal year-ends: Jun 2026 0.7x, Jun 2025 43.2x.
Analysts (ESMC)
Consensus None.
Total return (dividends reinvested) (ESMC)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +6.3% | -15.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +6.3% | -3.2% |
| Volatility (annualized) | 102.9% | 119.8% |
| Max drawdown | -44.0% (Feb 2026→Apr 2026) | -76.2% (Nov 2021→Jan 2023) |
ESMC revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $3.7M | 94.8% | +49.6% |
| Service | $202,111 | 5.2% | +62.2% |
| Total revenue | $3.9M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ESMC customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 12% of revenue, per the company's 10-K filed Oct 13, 2026. The company does not name it.
ESMC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Jun 2011) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 21:02 UTC)
| Price | USD 0.17 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.17 |
| Open | USD 0.18 |
| Day Range | USD 0.18 – 0.18 |
| 52-Week Range | USD 0.14 – 0.29 |
| Volume | 5,300 shares |
| Market Cap | $1.26M |
| Exchange | OQB |
Technical Analysis (ESMC)
Nexqual's technical model rates ESMC "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 24, 2026 at 21:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.9 (neutral) |
| vs SMA50 | Below (USD 0.17) |
| MACD | 0 (positive) |
Analyst Ratings (ESMC)
Wall Street analysts rate ESMC "None", per Nexqual as of October 24, 2026 at 21:02 UTC.
| Consensus Rating | None |
|---|
Earnings (ESMC)
Source: Nexqual, October 24, 2026 at 21:02 UTC.
Financials & Fundamentals (ESMC)
| Total Revenue | $12.74M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +50.20% |
| Gross Margin | +43.73% |
| Operating Margin | +14.72% |
| Profit Margin | +31.51% |
| ROE | +102.33% |
| Debt / Equity | 0.16 |
| Current Ratio | 2.94 |
| Total Cash | $3.07M |
| Total Debt | $974,740 |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$407,025 (-3.2% of revenue) |
Source: Nexqual, October 24, 2026 at 21:02 UTC.
Financial Health Score (ESMC)
Nexqual rates Escalon Medical Corp.'s overall financial health "Solid" across five dimensions, as of October 24, 2026 at 21:02 UTC.
| Growth | Strong — Revenue +50% YoY (latest Q) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $3M cash, no debt |
| Cash Flow | Weak — FCF negative: -$407K (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Strong — ROE 102%, ROA 0.4% |
Ownership (ESMC)
| Insider Ownership | +1.90% |
|---|---|
| Institutional Ownership | +7.91% |
| Shares Outstanding | 7.42M |
| Float | 7.27M |
| Short % of Float | +0.02% |
Source: Nexqual, October 24, 2026 at 21:02 UTC.
Leadership (ESMC)
Escalon Medical Corp. is led by Richard J. DePiano, President, CEO, General Counsel & Chairman of Board, per Nexqual as of October 24, 2026 at 21:02 UTC.
| President, CEO, General Counsel & Chairman of Board | Richard J. DePiano |
|---|
From Escalon Medical Corp.'s Latest SEC 10-K Filing (filed 2026-10-13)
Key Strengths & Strategy (as disclosed to the SEC)
- The FDA and comparable agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the manufacturing and marketing of pharmaceutical and medical device equipment and related disposables, including the obligation to adhere to the FDA's Good Manufacturing Practice regulations.
Partnerships
- Under a non-exclusive distribution agreement with AirGas, Inc. (AirGas"), the Company distributes packages of AirGas gases in canisters containing up to 25 grams of gas.
Legal & Regulatory Risks (Item 1A, quoted)
- Legal, Regulatory and Global
- The Company's products are subject to stringent ongoing regulation by the FDA and similar domestic and foreign health care regulatory authorities, and if the regulatory approvals or clearances of the Company's products are restricted or revoked, the Company could face delays that would impair the Company's ability to generate funds from operations.
- The Company may become involved in product liability litigation, which may subject the Company to liability and divert management attention.
- The Company's international operations could be adversely impacted by changes in laws or policies of foreign governmental agencies and social and economic conditions in the countries in which the Company operates.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATEC | Alphatec Holdings, Inc. | USD 11.11 | ▼ 2.2% |
| BFLY | Butterfly Network, Inc. | USD 6.76 | ▼ 0.73% |
| ESTA | Establishment Labs Holdings Inc | USD 63.8 | ▲ 0.44% |
| INSP | Inspire Medical Systems, Inc. | USD 71.11 | ▼ 2.13% |
| ALMR | Alamar Biosciences, Inc. | USD 30.69 | ▲ 3.26% |
| AXGN | AxoGen, Inc. | USD 38.06 | ▲ 3.76% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 21:02 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt